Cardinal Health

Overview

Cardinal Health is one of the three scaled U.S. pharmaceutical wholesalers, with a Pharmaceutical and Specialty Solutions segment that anchors channel access and an expanding services spine spanning Sonexus hub operations, Nuclear and Precision Health, at-Home Solutions, BioPharma Solutions, OptiFreight, and a Specialty Alliance MSO platform. The core buyer-relevance object is channel control: wholesale and specialty distribution, 3PL support, DSCSA and trade operations, and launch-scale product movement.

Cardinal Health is a large multi-business healthcare company; this profile focuses on the pharma manufacturer-facing services arm. The medical products and lab distribution segments are out of scope here. For launch teams, Cardinal is strongest when the commercial model needs distribution plus services adjacency rather than a standalone point solution. Oncology, rare disease, immunology, gastroenterology, diabetes, radiopharmaceutical, cell therapy, and gene therapy launches can create overlap among channel setup, patient access, provider reach, cold-chain handling, specialty pharmacy, and direct-to-patient logistics. Few vendors combine so many of those lanes under a scaled wholesaler relationship.

Drug Supply Chain Capability Model

The framework below standardizes how Rx Almanac evaluates drug-supply-chain capabilities, so buyers can compare vendors like-for-like while the readout column stays vendor-specific. For this table, Cardinal Health is evaluated as a large multi-business healthcare company focused here on its pharma manufacturer-facing services arm.

Capability	Buyer should compare	Cardinal Health readout
Wholesale and specialty distribution access	Wholesale scale, specialty distribution, limited distribution, provider/pharmacy reach, and trade partner relationships.	Core strength. Cardinal is one of the three scaled U.S. drug wholesalers and reports Pharmaceutical and Specialty Solutions as its main revenue and profit engine. Specialty revenue is expected to exceed $50B in FY2026. Strong fit when access support must connect to distribution. Sonexus is most relevant for specialty, rare, oncology, and high-cost therapies where reimbursement, financial assistance, and adherence support determine speed to therapy. Strategic differentiator with governance diligence. Navista, Specialty Networks, GI Alliance, Solaris, ION, and related assets can improve provider proximity, but manufacturers should validate compliance, data-use boundaries, referral neutrality, and contracting structure.
3PL warehousing and order fulfillment	Warehousing, pick/pack/ship, order management, service levels, launch stocking, and direct fulfillment.	Documented adjacency. BioPharma Solutions and Cardinal Health Pharmaceutical Distribution can support launches that need distributor, 3PL, and patient-service coordination rather than separately sourced vendors. Relevant for home-administered and chronic therapies. Edgepark and Advanced Diabetes Supply extend Cardinal into home medical supply and direct-to-patient logistics, especially diabetes and adjacent chronic-care categories.
Cold chain and specialty handling	Temperature-controlled storage, refrigerated/frozen shipping, biologics, specialty products, and excursion procedures.	Differentiated. Cardinal operates a national radiopharmacy network with roughly 160 nuclear pharmacy locations and 27 cyclotrons, giving radiopharma launches a channel asset that most hub or 3PL vendors cannot match.
DSCSA, serialization, and compliance controls	Serialization, tracing, verification, EPCIS, licensure, audit readiness, and regulatory compliance.	Not the main buying reason for Cardinal Health; validate only if the SOW includes dscsa, serialization, and compliance controls.
340B, returns, reverse logistics, or leakage controls	Returns, recalls, 340B controls, diversion monitoring, credit recovery, product destruction, and leakage management.	Not the main buying reason for Cardinal Health; validate only if the SOW includes 340b, returns, reverse logistics, or leakage controls.
Inventory visibility and trade reporting	Inventory data, demand signals, EDI/API feeds, order status, channel analytics, and manufacturer reporting.	RFP validation point. OptiFreight, distribution systems, and 3PL capabilities should be tested against service levels, exception handling, data feeds, and launch-specific geographies.

Buyer Fit

• Best fit: Specialty launches that need wholesale / specialty distribution plus one or more attached services: Sonexus hub support, 3PL, non-commercial pharmacy, radiopharmacy, at-home logistics, specialty provider reach, or manufacturer reporting.
• Strong therapy fit: Oncology, rare disease, immunology / autoimmune, GI, urology, diabetes, radiopharmaceuticals, biosimilars, cell therapy, and gene therapy where the product path is operationally complex.
• Best buyer motion: Use Cardinal when the manufacturer wants an enterprise-scale channel partner that can coordinate multiple functions. Use a narrower RFP if the only need is digital prior authorization, copay-only affordability tooling, or a pure patient-engagement platform.
• Caution: Cardinal’s breadth creates contracting and governance complexity. Buyers should clarify whether each service is delivered by Cardinal directly, an owned operating unit, a partner, or an acquired provider-platform asset.

Differentiators

• Big Three channel leverage: Cardinal can sit inside launch distribution strategy, trade operations, specialty distribution, and services design instead of entering only after the channel is already set.
• Sonexus flexibility: Sonexus is strongest where manufacturers want a tailored outsourced / hybrid model across reimbursement, pharmacy, clinical, affordability, and adherence support.
• Nuclear and Precision Health: The radiopharmacy footprint is a real differentiator for radiopharmaceutical and theranostic launches.
• Specialty provider proximity: Specialty Alliance, Navista, Specialty Networks, GI Alliance, Solaris, and ION give Cardinal a provider-facing specialty platform that can inform oncology, urology, GI, and autoimmune commercialization.
• At-home channel: Edgepark and Advanced Diabetes Supply add home medical supply and recurring patient logistics capabilities that traditional hub vendors do not usually own.
• Portfolio connectivity: Cardinal’s strongest pitch is not any single product; it is the ability to connect manufacturer, provider, patient, distribution, 3PL, and logistics workflows when the launch requires them.

RFP Questions

• Which Cardinal operating unit owns each workstream, and who is accountable when distribution, Sonexus, 3PL, OptiFreight, Nuclear, or at-Home workflows intersect?
• What launch-stocking, allocation, shortage, returns, recall, DSCSA, serialization, and temperature-excursion workflows are included in the base scope?
• What data will the manufacturer receive for inventory, orders, chargebacks, exceptions, adherence, benefit-verification status, prior authorization status, and patient-support activity?
• How can Sonexus support a fully outsourced model, a hybrid model, or selected services around manufacturer-owned CRM / hub technology?
• How are Specialty Alliance / MSO data, provider relationships, referrals, and commercial programs governed to preserve compliance and neutrality?
• Which radiopharmacy, PET, cyclotron, isotope, and nuclear-logistics capabilities are available in the launch geographies?
• How do Edgepark / ADS handoffs work for patient onboarding, refill reminders, payer exceptions, and home-supply continuity?
• What EDI/API integration, transportation-management, and reporting capabilities are live today versus roadmap?

Recent Activity

• 2026: Cardinal reported Q3 FY2026 revenue of $60.9B, up 11%, and raised fiscal 2026 outlook. Pharmaceutical and Specialty Solutions revenue was $56.1B, up 11%, and segment profit was $784M, up 18%.
• 2026: Cardinal said specialty remains a major growth driver, with specialty revenue expected to exceed $50B in FY2026.
• 2026: Cardinal announced increased Actinium-225 production capacity, reinforcing Nuclear and Precision Health as a strategic growth lane for radiopharmaceuticals.
• 2024 to 2025: Cardinal added or expanded Specialty Networks, ION, GI Alliance, Advanced Diabetes Supply, Urology America, and Solaris Health, deepening specialty provider and at-home capabilities across oncology, urology, GI, rheumatology, and diabetes.
• 2026: Ongoing: Sonexus continues to position around flexible hub models as manufacturers choose between outsourced, hybrid, and in-house patient-support operations.